biib022 antibody (Biogen Inc)
90
Structured Review
Biogen Inc
biib022 antibody
a " width="250" height="auto" />
Biib022 Antibody, supplied by Biogen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/biib022+antibody/biib021/pmc10383012-3-0-4
Average 90 stars, based on 1 article reviews
a " width="250" height="auto" />Biib022 Antibody, supplied by Biogen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/biib022+antibody/biib021/pmc10383012-3-0-4
Average 90 stars, based on 1 article reviews
biib022 antibody - by Bioz Stars,
2026-09
90/100 stars
Images
1) Product Images from "Costs and Causes of Oncology Drug Attrition With the Example of Insulin-Like Growth Factor-1 Receptor Inhibitors"
Article Title: Costs and Causes of Oncology Drug Attrition With the Example of Insulin-Like Growth Factor-1 Receptor Inhibitors
Journal: JAMA Network Open
doi: 10.1001/jamanetworkopen.2023.24977
a " title="The 16 IGF-1R Inhibitors and the Estimated Number of Patients Entered Into Clinical ... " property="contentUrl" width="100%" height="100%"/>
Figure Legend Snippet: The 16 IGF-1R Inhibitors and the Estimated Number of Patients Entered Into Clinical Trials
Techniques Used: Clinical Proteomics
Related Articles
Clinical Proteomics:Article Title: Current problems with systemic treatment of advanced hepatocellular cancer. Article Snippet: H epatocellular carcinoma (HCC) is an aggressive tumor that mostly occurs secondary to viral hepatitis infection, chronic liver disease, and cirrhosis.. With an estimated 711,000 new cases diagnosed annually, HCC is the fifth most common cancer worldwide and the third most common cause of cancer mortality.. The worldwide incidence of HCC varies according to the prevalence of hepatitis B and C infection, and the age-standardized incidence rates vary from 4.9 per 100,000 population in North America to 80 per 100,000 population in China. Article Title: Costs and Causes of Oncology Drug Attrition With the Example of Insulin-Like Growth Factor-1 Receptor Inhibitors Article Snippet: Article Title: Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Article Snippet: Article Title: Clinical development of inhibitors of the insulin-like growth factor receptor in oncology. Article Snippet: The insulin-like growth factor I receptor (IGF-IR) pathway plays a major role in cancer growth, tumor cell survival and resistance to therapy.. Ancillary evidence that targeting the IGF-IR may be useful in the treatment of cancer has been accumulating for almost two decades.. Today, more than two dozen compounds have been developed and clinical trials are underway for at least 12 of those. Article Title: Compositions for the treatment of solid tumors Article Snippet: Other non-limiting examples of anti-IGF1R antibodies for use in the methods of the present invention include Article Title: Ang-2-binding modular recognition domain complexes and pharmaceutical compositions thereof Article Snippet: In a specific embodiment, the antibody is selected from: cixutumumab (e.g., IMC-A12, Imclone), figitumumab (e.g., CP-751,871, Pfizer), AMG479 (Amgen), Article Title: Insulin-like growth factor receptor type I as a target for cancer therapy. Article Snippet: Finally BIIB022, a fully human non gylcosylated IgG4P antibody totally devoid of Fc-effector function and engineered with a gamma 1 like Article Title: Insulin-like growth factor receptor type I as a target for cancer therapy Article Snippet: IGF-IR & cancer The type I insulin-like growth factor receptor (IGF-IR) was cloned in 1986 [1].. It is the final effector of the endocrine growth hormonereleasing hormone peptide (GHRH)/growth hormone (GH)/IGF-I axis.. In normal cells, the GHRH secreted by the hypothalamus binds to GHRH receptors on somatotrophs in the anterior pituitary and regulates the synthesis and secretion of GH, which in turn results in IGF-I and IGF-II production by the liver. Mutagenesis:Article Title: Current problems with systemic treatment of advanced hepatocellular cancer. Article Snippet: H epatocellular carcinoma (HCC) is an aggressive tumor that mostly occurs secondary to viral hepatitis infection, chronic liver disease, and cirrhosis.. With an estimated 711,000 new cases diagnosed annually, HCC is the fifth most common cancer worldwide and the third most common cause of cancer mortality.. The worldwide incidence of HCC varies according to the prevalence of hepatitis B and C infection, and the age-standardized incidence rates vary from 4.9 per 100,000 population in North America to 80 per 100,000 population in China. Article Title: Costs and Causes of Oncology Drug Attrition With the Example of Insulin-Like Growth Factor-1 Receptor Inhibitors Article Snippet: Article Title: Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Article Snippet: Article Title: Clinical development of inhibitors of the insulin-like growth factor receptor in oncology. Article Snippet: The insulin-like growth factor I receptor (IGF-IR) pathway plays a major role in cancer growth, tumor cell survival and resistance to therapy.. Ancillary evidence that targeting the IGF-IR may be useful in the treatment of cancer has been accumulating for almost two decades.. Today, more than two dozen compounds have been developed and clinical trials are underway for at least 12 of those. Article Title: Compositions for the treatment of solid tumors Article Snippet: Other non-limiting examples of anti-IGF1R antibodies for use in the methods of the present invention include Article Title: Ang-2-binding modular recognition domain complexes and pharmaceutical compositions thereof Article Snippet: In a specific embodiment, the antibody is selected from: cixutumumab (e.g., IMC-A12, Imclone), figitumumab (e.g., CP-751,871, Pfizer), AMG479 (Amgen), Article Title: Insulin-like growth factor receptor type I as a target for cancer therapy. Article Snippet: Finally BIIB022, a fully human non gylcosylated IgG4P antibody totally devoid of Fc-effector function and engineered with a gamma 1 like Article Title: Insulin-like growth factor receptor type I as a target for cancer therapy Article Snippet: IGF-IR & cancer The type I insulin-like growth factor receptor (IGF-IR) was cloned in 1986 [1].. It is the final effector of the endocrine growth hormonereleasing hormone peptide (GHRH)/growth hormone (GH)/IGF-I axis.. In normal cells, the GHRH secreted by the hypothalamus binds to GHRH receptors on somatotrophs in the anterior pituitary and regulates the synthesis and secretion of GH, which in turn results in IGF-I and IGF-II production by the liver. Activity Assay:Article Title: Current problems with systemic treatment of advanced hepatocellular cancer. Article Snippet: H epatocellular carcinoma (HCC) is an aggressive tumor that mostly occurs secondary to viral hepatitis infection, chronic liver disease, and cirrhosis.. With an estimated 711,000 new cases diagnosed annually, HCC is the fifth most common cancer worldwide and the third most common cause of cancer mortality.. The worldwide incidence of HCC varies according to the prevalence of hepatitis B and C infection, and the age-standardized incidence rates vary from 4.9 per 100,000 population in North America to 80 per 100,000 population in China. Article Title: Costs and Causes of Oncology Drug Attrition With the Example of Insulin-Like Growth Factor-1 Receptor Inhibitors Article Snippet: Article Title: Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Article Snippet: Article Title: Clinical development of inhibitors of the insulin-like growth factor receptor in oncology. Article Snippet: The insulin-like growth factor I receptor (IGF-IR) pathway plays a major role in cancer growth, tumor cell survival and resistance to therapy.. Ancillary evidence that targeting the IGF-IR may be useful in the treatment of cancer has been accumulating for almost two decades.. Today, more than two dozen compounds have been developed and clinical trials are underway for at least 12 of those. Article Title: Compositions for the treatment of solid tumors Article Snippet: Other non-limiting examples of anti-IGF1R antibodies for use in the methods of the present invention include Article Title: Ang-2-binding modular recognition domain complexes and pharmaceutical compositions thereof Article Snippet: In a specific embodiment, the antibody is selected from: cixutumumab (e.g., IMC-A12, Imclone), figitumumab (e.g., CP-751,871, Pfizer), AMG479 (Amgen), Article Title: Insulin-like growth factor receptor type I as a target for cancer therapy. Article Snippet: Finally BIIB022, a fully human non gylcosylated IgG4P antibody totally devoid of Fc-effector function and engineered with a gamma 1 like Article Title: Insulin-like growth factor receptor type I as a target for cancer therapy Article Snippet: IGF-IR & cancer The type I insulin-like growth factor receptor (IGF-IR) was cloned in 1986 [1].. It is the final effector of the endocrine growth hormonereleasing hormone peptide (GHRH)/growth hormone (GH)/IGF-I axis.. In normal cells, the GHRH secreted by the hypothalamus binds to GHRH receptors on somatotrophs in the anterior pituitary and regulates the synthesis and secretion of GH, which in turn results in IGF-I and IGF-II production by the liver. |
